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Abstract 
 
To identify rate-limiting steps in T cell-independent type 2 (TI-2) antibody 
production against polysaccharide antigens, we performed a genome-wide 
screen by immunizing several hundred pedigrees of C57BL/6 mice 
segregating ENU-induced mis-sense mutations. Two independent mutations, 
Tilcara and Untied, were isolated that semi-dominantly diminished antibody 
against polysaccharide but not protein antigens. Both mutations resulted from 
single amino acid substitutions within the kinase domain of Protein Kinase C 
Beta (PKCβ). In Tilcara, a Ser552>Pro mutation occurred in helix G, in close 
proximity to a docking site for the inhibitory N-terminal pseudosubstrate 
domain of the enzyme, resulting in almost complete loss of active, 
autophosphorylated PKCβI whereas the amount of alternatively spliced 
PKCβII protein was not markedly reduced. Circulating B cell subsets were 
normal and acute responses to BCR-stimulation such as CD25 induction and 
initiation of DNA synthesis were only measurably diminished in Tilcara 
homozygotes, whereas the fraction of cells that had divided multiple times 
was decreased to an intermediate degree in heterozygotes. These results, 
coupled with evidence of numerous mis-sense PRKCB mutations in the 
human genome, identify Prkcb as a genetically sensitive step likely to 
contribute substantially to population variability in anti-polysaccharide 
antibody levels. 
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Introduction 
 
A hallmark of the adaptive immune system is the production of antibodies by 
B cells targeting varying types of antigens. Genetic studies in mice have 
distinguished different routes for antibody production depending on the nature 
of the antigen. Firstly, antigens have been classified as eliciting either T cell-
dependent or T cell-independent (TI) responses based on the ability to induce 
antibodies to a given antigen in athymic nude mice1. Antigens that elicit T-
independent antibody responses have been further sub-divided into TI-1 or TI-
2 antigens based on their ability to stimulate responses in the X-linked 
immunodeficiency (Xid) mouse strain, which has a crippling Btk mutation that 
affects some intracellular signals elicited by antigen binding to the B cell 
antigen receptors (BCR). Xid mice are capable of making antibodies against 
TI-1 antigens, such as bacterial lipopolysaccharide or flagellin, because these 
signal B cell proliferation through Toll-like receptors2. By contrast, Xid mice fail 
to make antibodies to TI-2 antigens such as the polysaccharide envelopes of 
some bacteria or synthetic polysaccharides such as Ficoll, because these 
antigens signal B cell proliferation by extensively cross-linking the BCR into 
large aggregates that persist on the cell surface1, 3, 4. TI-2 responses are 
mediated primarily by the secretion of short-lived IgM isotype antibodies by 
marginal zone (MZ) B cells in the spleen5 and the B-1 cells in the serous 
cavities6, 7. 
 
In a T-independent antibody response, the stimulation of the B cell receptor 
(BCR) leads to the phosphorylation of immunoreceptor tyrosine-based 
activation motifs in the cytoplasmic tails of the signal transducing molecules 
CD79a (Igα) and CD79b (Igβ). This allows the phosphorylation of multiple 
signalling kinases such as Bruton’s tyrosine kinase (Btk) and the 
phospholipase c gamma-2 (PLCγ2)-mediated elevation of intracellular 
calcium. These kinases activate protein kinase c beta (PKCb) which starts a 
phosphorylation cascade activating the Card11/Malt1/Bcl-10 complex. This 
results in the recruitment of the nuclear factor kappa B transcription factor to 
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inducible genes that stimulate B cell proliferation and TI-2 antibody 
production. 
 
Defects in TI-2 antibody responses result in increased susceptibility to 
encapsulated bacterial infections such as Haemophilus influenza type b, 
Neisseria meningitides and Streptococcus pneumoniae8. These infections 
severely impact young children particularly in the developing world. Chronic 
infection and poor disease management can lead to mortality. Lower antibody 
production against these antigens is correlated with recurrent infection9-11 but 
the underlying basis for population variation is not known. Further 
understanding of the underlying genetic alterations that make individuals more 
susceptible to these diseases are important for the identification of therapeutic 
targets for the disease and to enhance vaccination and immunisation 
strategies.  
 
A unique feature of modern humans is the massive degree of population 
expansion that has occurred in the last several hundred generations. Deep 
sequencing efforts have recently revealed that this growth has resulted in an 
equally massive increase in the frequency of heterozygous deleterious 
mutations12-16 with each person carrying on average 100 deleterious 
mutations in the genome with approximately 20 being complete loss of 
function variants17. Each of these mutations are individually too recently 
arising and rare in the population at large to have yet been removed by 
purifying selection, yet cumulatively they amount to a large genetic burden. 
Rare variants account for 95% of the protein-altering mutations predicted to 
be deleterious in the current generation of humans, and account for ~25% of 
the deleterious mutations in any individual’s genome. Based on the de-novo 
mutation rate in human reproduction (1.4×10-8/bp), the current generation of 
humans is now large enough (6×109 individuals) to saturate every nucleotide 
of the genome with de-novo mutations12. Among this burden of recent 
mutations will be many unique heterozygous mutations in the large network of 
genes that control antibody production. Heterozygous mutations that affect 
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rate-limiting steps in antibody production will account for a substantial amount 
of inherited variability in antibody formation, but no systematic efforts have yet 
been made to identify these rate-limiting steps.     
 
In this study, we have taken an experimental approach in mice to evaluate the 
impact of increasing the genome-wide burden of rare variants on TI-2 
antibody formation against polysaccharide antigens. We used N-ethyl-N-
nitrosurea (ENU) mutagenesis of inbred C57BL/6 mice to increase the 
frequency of single nucleotide variants, coupled with systematic screening for 
variability in the antibody response following immunization with a haptenated 
polysaccharide, NP-Ficoll18. Two semi-dominant mutations were isolated 
causing selective deficits in TI-2 antibody response, and both were due 
substitutions in conserved residues in the catalytic domain of Protein kinase c 
beta (Prkcb). These results identify PRKCB as a rate-limiting point in the 
network of genes controlling TI-2 antibody, and provide novel animal models 
to analyze the biochemistry of the two PKCβ enzyme isoforms.  
 
Results 
 
Generation of the Tilcara and Untied mutant mice and identification of 
the causative mutation in Prkcb 
A genetic screen was performed to identify genes that are critical for T-cell 
independent antibody production. First generation offspring (G1) from ENU-
treated inbred C57BL/6 male mice were used as founders for separate 
inbreeding pedigrees by breeding with wild-type females, and subsequently 
intercrossing their G2 progeny to generate a G3 generation. Twelve-week-old 
G3 offspring from 130 pedigrees were screened by immunization with a panel 
of antigens that differentially elicit T-cell independent and T-dependent 
antibody responses. T cell-dependent antibody response were measured by 
immunizing each G3 animal with alum-precipitated chicken gamma globulin 
coupled to hapten arsonate (ABA-CGG) and heat killed Bordetella pertussis 
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(BP). After 5 weeks, the mice were re-immunized with ABA-CGG to test T-cell 
dependent memory and affinity maturation, and immunized at the same time 
with NP-Ficoll, which elicits a T-cell independent type 2 (TI-2) antibody 
response18, 19. Three of five mice tested in the Tilcara pedigree exhibited 
lower TI-2 responses compared to littermate counterparts (Figure 1a and b), 
but had normal T-dependent responses indicating that these mice have no 
general problem in the generation of specific antibodies.  
 
To link the mutation responsible for low TI-2 antibody to a single 
chromosome, an F2 intercross was performed between offspring from an 
affected C57BL/6 (B6) G3 mouse and a wild-type C57BL/10 (B10) mouse. 
Immunization of the F2 offspring with NP-Ficoll identified three groups of 
animals. The first group had a very low TI-2 antibody response (“affected”), a 
second group had normal levels of antibodies (“unaffected”) and a third group 
showed an intermediate response. Pooled DNA samples from affected and 
unaffected mice was tested using a panel of single nucleotide polymorphisms 
(SNPs) between the B6 and B10 strains, linking the Tilcara trait to 
chromosome 7 distal to SNP rs1347954 at 109 Mb. Because of the semi-
dominant inheritance the location of the mutation was further refined by 
immunizing offspring from a cross between (C57BL/6×CBA)F1 animals with 
an intermediate response and wild-type B6 mice. Genotyping of intermediate 
responders and unaffected animals localised the mutation to an 8.3 Mb 
interval (Figure 1c) containing 199 predicted genes, including 16 genes with 
known immunological function. Three of these, Cd19, Cd11b and Prkcb, were 
selected as candidate genes for sequencing of splenic mRNA, revealing a 
single T-to-C point coding sequence mutation in Prkcb at base pair 1654 
(Figure 1d). 
 
A second screen of another cohort of ENU mutagenized mice revealed 
another mouse strain, Untied, that also displayed a semi-dominant defect in 
IgM antibody selectively against TI-2 antigens (Figure 1e). Sequencing of 
Prkcb revealed an independent mutation in this strain: in this case a T to C 
transition at position 1469 of the Prkcb transcript. The Tilcara and Untied 
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mutations both result in single amino acid substitutions of highly conserved 
residues in the PKCβ kinase domain. Untied results from a tyrosine to 
histidine substitution at amino acid 417. This alters a residue that is absolutely 
conserved from mammals to invertebrates, in the middle of beta sheet 5 near 
the conserved gatekeeper residue (Met420) that controls access to the ATP 
binding pocket (Figure 1f, g and h). In Tilcara, Ser552 in the middle of alpha 
helix G on the C-lobe of the kinase domain, on the lower lip of the substrate 
binding cleft (Figure 1f, g and h), is mutated to a proline that would be 
predicted to break the helical structure. The mutated S552 is absolutely 
conserved from mammals to fish and highly conserved between different 
murine PKC family members (Figure 1i). The genetic evidence that these are 
causal is thus supported by three independent mutations, since a comparable 
semi-dominant loss of TI2 antibody responses was also observed in Prkcb 
knockout mice20. 
 
Two isoforms of protein kinase C beta, PKCβI and PKCβII are produced in 
mice, humans and other mammals by alternative mRNA splicing of exons 
encoding PKCβI residues 622-671 (622-673 in PKCβII). Hence the S552P 
Tilcara mutation affects the part of the protein that is common to both 
isoforms. Western blotting with antibodies specific for one or other isoform 
revealed a consistent reduction in the PKCβI isoform in purified B cell lysates 
from Prkcbtil/til mice compared to wild-type controls, while Tilcara 
heterozygous mice had intermediate protein expression (Figure 2a). By 
contrast, there was no consistent decrease in the PKCβII isoform (Figure 2a). 
Following translation, both PKCβI and PKCβII undergo sequential 
phosphorylation at threonine and serine residues to become catalytically 
active, and these modifications can be revealed indirectly by slower mobility in 
SDS-PAGE and directly by phospho-specific antibodies21. When the mutant 
or wild-type PKCβI isoform was expressed in 293T cells, the Tilcara S552P 
mutation caused almost complete absence of the slower migrating PKCβI 
form although the more rapidly migrating species was present at comparable 
levels in soluble cytoplasmic component of the NP-40 lysed-transfected with 
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mutant or wild-type vectors (Figure 2b).  The S552P mutation had a similar 
effect when the PKCβII isoform was expressed in transfected 293T cells, 
although a small amount of slowly migrating protein was present in this case. 
The first post-translational modification step in the maturation of PKCβI and II, 
involving Thr500 phosphorylation in the kinase domain activation loop by 
phosphoinositide-dependent kinase-1 (PDK-1)22 was tested by Western 
blotting B cell lysates with an antibody to phospho-T500 (Figure 2c). 
Comparable amounts of phospho-T500 PKCβ were present in wild-type, 
heterozygous and Prkcbtil/til B cell lysates. This activation loop phosphorylation 
in turn allows PKCβI to auto-phosphorylate T642 in the turn motif and S660 in 
the hydrophobic motif of the alternatively spliced C-terminal tail, releasing the 
fully active enzyme into the cytosol23. Western blotting with phospho-T642 
PKCβI antibody revealed a profound decrease in autophophorylated protein in 
B cells from homozygous Prkcbtil/til  mutant mice and an intermediate deficit in 
heterozygotes (Figure 2d). Thus, the S552P mutation almost completely 
eliminates the fully active species of PKCβI in B cells, establishing that the 
Prkcbtil/til mutation diminishes PKCβ function both in situ in primary B cells and 
when the mutant protein is expressed on its own in a heterologous cell line. 
 
Diminished basal serum IgM and IgG3 and T-independent antibody 
responses in Tilcara mouse 
The semi-dominant biochemical effects of the Tilcara S552P PKCβ mutation 
defined above were accompanied by semi-dominant effects on antibody 
production to the TI-2 antigen, NP-Ficoll (Figure 3a). When NP-specific IgM 
and IgG3 were measured in a large cohort of animals seven days post 
immunization, Tilcara heterozygous mice made significantly less antibody 
than wild-type controls while Prkcbtil/til homozygotes made lower responses 
than heterozygotes. Likewise, in unimmunised age-matched mice there was a 
semi-dominant decrease in natural serum IgM antibody (Figure 3b), which 
decreased ~50% and ~75% in Tilcara heterozygous and homozygous mice, 
respectively, compared to wild-type controls. Basal serum IgG3 was also 
decreased ~75% in Tilcara heterozygous and homozygous mice. 
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Serum IgG1 and total IgG were nevertheless comparable between mutant 
and wild-type animals (Figure 3b). Likewise, there were normal T cell 
dependent antibody responses following immunization with alum precipitated 
chicken gamma globulin coupled to hapten arsonate (ABA-CGG) and heat 
killed Bordetella pertussis (BP), which depend on TH2 and TH1 cells to elicit 
CGG-specific IgG1 and BP-specific IgG2c response24. There were no 
significant differences in these antibody responses between wild-type mice 
and Tilcara heterozygous or homozygous animals (Figure 3c). The S552P 
mutation in Prkcb thus causes a selective defect in T-independent antibody 
responses. 
 
Lymphocyte development and decreased B-1a cells in Tilcara mouse 
B lymphocyte development and peripheral subsets were assessed in Tilcara 
mice by flow cytometry, with particular focus on B cells that are responsible 
for TI-2 antibody responses – marginal zone and B-1 cells. In the bone 
marrow, no significant differences in percentages of early pro-B/pre-B 
(B220loIgMlo), immature (B220loIgMhi) and mature (B220hiIgMhi) B cells could 
be detected between wild-type, Prkcbwt/til, Prkcbtil/ti mice (Figure 4a). Similarly, 
there was no discernable effect of the mutation on transitional 1 
(CD93hiIgMloCD23lo), transitional 2 (CD93hiIgMhiCD23hi), transitional 3 
(CD93hiIgMloCD23hi), follicular (CD93loCD23hiCD21int) and marginal zone 
(CD93loCD23loCD21int) B cell subpopulations in the spleen (Figure 4b). Cell 
surface IgM was downregulated normally during maturation of follicular B cells 
in Tilcara homozygotes: a result that stands in contrast to mutations in BTK25 
or PLCγ226 immediately upstream of PKCβ or with mutations in CARD1127 
immediately downstream, which cause surface IgM to remain high on follicular 
B cells. T cell subsets in the thymus, lymph nodes and spleen were also 
comparable (data not shown). The only striking abnormality in lymphocyte 
development was in the peritoneal cavity, where CD11bhiIgMhi B-1 cells were 
markedly decreased in frequency selectively in Prkcbtil/til homozygous mice 
compared with wild-type and Prkcbwt/til heterozygotes (Figure 4c). Sub-division 
of the B-1 cells into CD5+ B-1a and CD5- B-1b subpopulation revealed that 
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this difference was attributed largely to the near absence of the B-1a 
population in homozygous mutant animals (Figure 4c). 
 
Competitive mixed bone marrow chimeras were produced by transplanting 
irradiated mice with equal amounts of bone marrow from CD45.1 wild-type 
and CD45.2 Prkcbtil/til donors. Analysis of the reconstituted chimeric animals 
showed that the Prkcbtil/til mutation did not affect the numbers of B and T cell 
subsets in central and peripheral lymphoid tissue, which were drawn equally 
from mutant and wild-type lymphocytes. By contrast, peritoneal B-1a cells and 
to a lesser extend marginal zone cells were preferentially derived from the 
wild-type lymphocytes and not from those harbouring the Prkcbtil/til mutation, 
demonstrating an intrinsic, cell-autonomous requirement for fully active PKCβ 
selectively in the formation of B1 B cells (Supplementary Table1 and 
supplementary Figure 1). 
 
Recessive deficits in the acute BCR-response 
We next analysed the consequences of the S552P Prkcbtil mutation on B cell 
responses to receptor stimulation in vitro. Increased intracellular calcium after 
BCR stimulation was monitored using the calcium-sensing dye, Indo-1, in co-
cultured CD45.1 wild-type and CD45.2 Prkcbtil/til cells stimulated with sub-
optimal and optimal concentrations of anti-IgM antibody (Figure 5a). By 
overlaying the paired responses from mutant and wild-type cells stimulated 
together, there was no discernable difference in the intracellular calcium 
response between wild-type and Prkcbtil/til cells. Thus, the early steps in BCR 
signalling leading to Plcγ activation, which lies immediately upstream of 
PKCβ, appeared unaffected by the Prkcbtil mutation. 
BCR, CD40 or TLR signalling induces an early wave of gene transcription in B 
cells that includes the cell surface protein, CD25. CD25 induction by the BCR 
but not CD40 or TLR4 is compromised in B cells with mutations in Card1127, a 
known immediate substrate of PKCβ28, 29. Flow cytometric analysis showed 
that CD25 was induced by anti-IgM stimulation of wild-type B cells but poorly 
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induced in homozygous mutant Prkcbtil/til B cells stimulated in the same 
culture (Figure 5b and c). By contrast, CD25 was induced equivalently in 
mutant and wild-type B cells stimulated with 1 µg/ml IgM + 10µg/ml CD40L or 
the TLR4 agonist, LPS. Unlike the homozygous mutant B cells, Tilcara 
heterozygous B cells exhibited no discernable decrease in CD25 induction 
following anti-IgM stimulation (Figure 5b and c). 
 
Entry of B cells into cell cycle was measured by incorporation of radioactive 
thymidine after 2 days in culture. Spleen cells from individual homozygous 
Prkcbtil/til mice had markedly diminished thymidine incorporation in response 
to BCR-stimulation, whereas their response to LPS (TLR4), CpG (TLR9) or 
antibody to CD3 was normal (Figure 6a-d). Heterozygous Prkcbtil/+ B cells did 
not have significantly reduced DNA incorporation upon anti-IgM stimulation. 
The combination of anti-IgM and anti-CD40 stimulation partially restored the 
initiation of proliferation in Prkcbtil/til cells (Figure 6e). Measurement of B cell 
division by dilution of the intracellular dye, CFSE, yielded similar results and 
enabled cell autonomous effects of the Prkcb mutation to be confirmed by 
comparing CFSE dilution in co-cultured CD45.1 normal B cells 5 days post 
stimulation. Few homozygous mutant B cells had divided multiple times in 
response to anti-IgM, while the percentage of divided Tilcara heterozygous B 
cells was significantly lower than in wild-type controls (Figure 6f and g). 
Stimulation with anti-IgM and CD40 greatly enhanced the fraction of wild-type 
B cells that had divided multiple times, but only modestly increased the 
response of homozygous mutant B cells, while the response of heterozygous 
mutant B cells was clearly intermediate. Collectively, these results indicate 
that the semi-dominant effects of Prkcb mutation on BCR-induced proliferation 
are difficult to discern during the entry into cycle but become more apparent 
when measured after several cell divisions. This may reflect either less re-
initiation of subsequent cell divisions in heterozygous mutants or diminished 
survival of their divided progeny compared to the wild-type B cells in the same 
culture. 
 
 12 
Discussion 
 
The results above represent a genome-wide experimental approach to identify 
rate-limiting steps in TI-2 antibody production that are particularly sensitive to 
heterozygous mis-sense mutations. Two independent, semi-dominant 
mutations were revealed, Tilcara and Untied, both changing individual amino 
acids within the catalytic domain of PKCβ. Semi-dominant loss of TI-2 
antibody was also reported in Prkcb knockout mice20. The findings identify 
Prkcb as a key genetic node with a gene-dosage sensitive role selectively in 
BCR-induced cell division and TI-2 antibody responses.  In contrast with these 
semi-dominant effects on TI-2 antibody responses, formation of B1a B cells in 
the peritoneal cavity and basal production of serum IgM and IgG3 were only 
diminished in Tilcara homozygous mutants. Likewise, early responses to 
BCR-stimulation such as CD25 induction and initiation of DNA synthesis were 
only measurably diminished in homozygotes, whereas the fraction of cells that 
had divided multiple times was decreased to an intermediate degree in 
heterozygotes.  
 
In Tilcara, the Ser552>Pro mutation differential affected the alternatively 
spliced PKCβI and PKCβII isoforms. The active, autophosphorylated PKCβI 
species was preferentially diminished and the overall amount of PKCβI 
protein was greatly decreased in homozygotes and markedly decreased in 
heterozygotes, whereas the overall amount of PKCβII protein was not 
markedly reduced. More complete loss of autophosphorylated PKCβI than 
PKCβII was also observed when tagged versions of the proteins were 
transiently expressed in 293 cells. Preferential loss of autophosphorylated 
PKCβI has several possible explanations. Ser552 lies in helix G of the catalytic 
domain, which forms a lower lip on the catalytic site and contains a series of 
acidic residues, EDEDELFQS552, that interact with basic Arg or Lys residues 
in the pseudosubstrate inhibitory domain that lies at the PKCβ N-terminus30-32. 
Serine552 is absolutely conserved in vertebrates, and its substitution by proline 
would be predicted to break the alpha-helical structure and diminish binding to 
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the pseudosubstrate inhibitory domain and to kinase substrates. Decreased 
substrate binding may diminish autophosphorylation to generate the fully 
active species, while decreased binding to the pseudosubstrate domain may 
accelerate dephosphorylation and degradation of the kinase. When the 
pseudosubstrate domain is allosterically dislodged from Helix G upon PKCβ 
binding to membrane lipids, this opening up is rapidly followed by 
dephosphorylation of the kinase and, in the case of PKCβI, rapid protein 
degradation33. By contrast, PKCβII degradation after dephosphorylation 
occurs more slowly, and this may explain the selective loss of PKCβI in 
Tilcara B cells.  
   
The resulting semi-dominant immunological effects of the Tilcara mutation 
favour the view that catalytically active PKCβI is the critical enzyme isoform 
for progressive B cell division in response to BCR-crosslinking and for TI-2 
antibody formation. This genetic inference is supported by biochemical 
evidence that PKCβI preferentially associates with other essential proteins for 
BCR-induced NFκB signalling and proliferation, in particular BTK and 
CARD1129, 34.  
 
The immune phenotype of Tilcara homozygotes had a number of significant 
differences compared to knockout mice that completely lack both PKCβ 
isoforms. PKCβ-null mice had defects in both TI-2 and TD antibody 
responses20, whereas Tilcara homozygous mice had low TI-2 antibody 
responses but normal TD antibody responses. PKCβ-null mice also had fewer 
mature IgMloIgDhi follicular B cells in the spleen35 and fewer mature follicular B 
cells that had recirculated to the bone marrow36, whereas the numbers of both 
subsets were normal in Tilcara homozygotes. There are two plausible 
explanations for the different phenotypes. Firstly, the Prkcbtil/til mutation may 
result in the expression of small amounts of catalytically competent PKCβI 
kinase with residual activity. This activity may be insufficient for the stimulation 
of TI-2 antibody responses but sufficient for TD responses and mature B cell 
survival. TI-2 antibody responses are highly dependent on BCR cross-linking 
and stimulation via the BCR receptor8. In contrast, the TD antibody response 
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involves other mitogenic signals such as CD40 ligand37, that may activate 
complementary signalling pathways and kinases that counteract the partial 
defect in PKCβI kinase activity. This hypothesis is also supported by the 
observation that addition of CD40L to the anti-IgM stimulation was able to 
normalize upregulation of CD25 and helped at least partially to overcome the 
defective proliferation in response to anti-IgM alone. Alternatively, there may 
be a division of labor between the PKCβI and PKCβII isoforms, where the 
PKCβI isoform is involved in TI-2 antibody response, whereas the PKCβII 
isoform that was less compromised in Tilcara is involved in TD antibody 
production and mature B cell survival. Support for this possibility comes from 
the observation that PKCβI and PKCβII play different roles in the insulin 
receptor signalling pathway38. It would be interesting in future studies to 
engineer mice that selectively lack PKCβI protein entirely while retaining 
normal PKCβII. 
 
Heterozygous mis-sense mutations, like those in Tilcara and Untied, have 
accumulated in the current human population at a massive scale because of 
exponential population growth and outbreeding12-16. Whereas offspring of 
ENU-mutagenized mice inherit ~40 novel mis-sense variants, a “normal” 
current human genome inherits more than 5 000 mis-sense variants including 
300-600 that are predicted to be deleterious to protein function and 75-150 
that represent rare, recent deleterious mutations yet to be subject to purifying 
selection16. Hence, the finding of two heterozygous missense Prkcb mutations 
that reduce TI-2 antibody responses amongst several hundred ENU mouse 
pedigrees can be extrapolated to predict at least a similar ~1% frequency in 
human families. Indeed, recent exome sequence data from 2 440 individuals16 
annotates 21 independent mis-sense mutations in PRKCB including many in 
the kinase domain (http://evs.gs.washington.edu/EVS/). It will important to test 
if PRKCB is equally gene-dosage sensitive in human B cells. Extrapolating 
from the mouse experiments here, and from evidence that ~20% of missense 
mutations are profoundly crippling39, of the 1% of people carrying unique 
PRKCB variants at least 20% of these individuals (0.2% of the population) 
would be expected to make less antibody to polysaccharide antigens of 
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enveloped bacteria but exhibit normal circulating B cell subsets, serum IgG, 
TD antibody to tetanus toxoid and MMR vaccination. One could readily 
envisage additive or epistatic interactions between heterozygous mutations in 
PRKCB and in other rate-limiting genes for BCR-induced proliferation, as we 
have shown occurs between heterozygous mutations in Lyn, Cd22 and Ptpn6 
encoding interacting negative regulators of BCR signalling40. These 
experimental results, coupled with human exome sequencing, thus open up a 
new way to analyse variability in humoral immunity in the wider population, 
among individuals that would not be defined as having a primary 
immunodeficiency.   
 
Materials and methods 
 
ENU-treatment of mice. 8-15 week old male C57BL/6 mice were treated with 
three doses of 100 mg/kg N-ethyl-N-nitrosurea (Sigma) prepared in 10% 
ethanol, citrate buffer (pH5.0), one week apart, as previously described 41. 
The mice were housed in specific pathogen free conditions at the Australian 
National University Bioscience Facility or the Scripps Research Institute 
vivarium. All animal procedures were approved by the Australian National 
University Animal Ethics and Experimentation Committee or the Institutional 
Animal Care and Use Committee of the Scripps Research Institute.  
Immunization and enzyme-linked immunosorbent assay. Mice were 
immunized by intraperitoneal injections. For TI-2 immune response, the mice 
received 25 μg NP-Ficoll (Biosearch Technology) in sterile PBS. For TD 
responses, mice received 50 μg CGG with hapten arsonate (Biosearch 
Technology) and 5×108 whole killed Bordetella pertussis (Lee Labs, Becton 
Dickinson).  Total and antigen specific antibodies in serially diluted sera were 
detected by enzyme-linked immunosorbent assay on Maxisord plates coated 
with CGG, sonicated B. pertussis or NP-Ficoll. Bound antibodies were 
detected with alkaline phosphate antibodies to specific mouse isotypes using 
the phosphatase substrate system. Plates were read at 405 to 650 nm using a 
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Thermomax microplate reader. The titres for serum samples were calculated 
as the difference of serum concentrations required to achieve 50% maximum 
optical density compared to a standard control ran on each plate. 
Typing of mutation. Candidate mRNAs were amplified in 300-800 bp 
fragments using polymerase chain reactions from spleen cDNA and 
resequenced by the Biomolecular Resource Facility (JCSMR, ANU) using the 
ABI 3730 capillary sequencer and analysed using the Sequencher 4.2 
software. The primers for Prkbc were: 
PrkcbA forward primer: 5' CGCGCAAGATGGCTGACC 3' 
PrkcbA reverse primer: 5' CGATGTGGGCCTGGATATAG 3' 
PrkcbB forward primer: 5' AAGCGCTGCGTGATGAAC 3' 
PrkcbB reverse primer: 5' TGGCCAATCTTGGCTCTC 3' 
PrkcbC forward primer: 5' TGTGGATGGCTGGTTCAA 3' 
PrkcbC reverse primer: 5' AATACAGCATGGGGCTCCT 3' 
PrkcbD forward primer: 5' GCTCCATTCCTGCTTCCA 3' 
PrkcbD reverse primer: 5' CTTGCCTGGGTGTTTGGT 3' 
PrkcbE forward primer: 5' CCGTTTGAAGGGGAGGAT 3' 
PrkcbE reverse primer: 5' CATGGCCACTCTAGCCTCA 3' 
 
Cell isolation and flow cytometry. Spleens and thymi were harvested from 
mice and single cells suspensions were prepared by sieving and gentle 
pipeting through a 70 μm nylon mesh filter. Bone marrow cells were flushed 
out from tibias and femurs, which were aseptically cut at both ends. Peritoneal 
cells were collected by abdominal lavage. Blood was collected by retro-orbital 
bleeds from live mice.  For surface straining, samples were stained with the 
appropriate primary and secondary antibodies. A BD LSRII Benchtop Flow 
Cytometer with FACS Diva was used for acquisition of flow cytometric data, 
and Flowjo (Treestar, Inc.) was used for analysis. 
 
Antibodies. Antibodies used for flow cytometry were from BD unless other 
wise indicated: 7-Amino-actinomycin D (Calbiochem), anti-mouse CD11b-
APC/FITC (eBioscience), anti-mouse CD16/CD32 (Stemcell Technologies), 
anti-mouse CD1d-PE, anti-mouse CD21/CD35-FITC/PE, anti-mouse CD23-
Formatted: Spanish
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PE Cy7 (eBioscience), anti-mouse CD25-APC, anti-mouse CD4-FITC/PE 
Cy7, anti-mouse CD43-PE, anti-mouse CD45.1-biotin/FITC, anti-mouse 
CD45.1-Alexa Flour 700 (BioLegend), anti-mouse CD45.2-Biotin/PE, anti-
mouse CD45.2-Pecific blue (BioLegend), anti-mouse CD45R-Alexa Fluor 
405/APC-Cy7/FITC/PE-Cy7/PerCP, anti-mouse CD5-PE, anti-mouse CD62L-
PE, anti-mouse CD69-FITC/PE Cy7, anti-mouse CD8- Alexa Fluor 700, 
PerCP Cy5.5 (eBioscience), anti-mouse CD86-APC/PE, anti-mouse CD93-
APC (eBioscience), anti-mouse IgM-APC/FITC/PE Cy5.5, anti-mouse TCR 
beta- APC-Alexa Fluor 750 (eBioscience), streptavidin-PE/ PerCP/APC and 
streptavidin-Qdot 605 (Invitrogen). Antibodies used for ELISA: goat anti-
mouse IgG/IgG1/IgG3/IgM-alkaline phosphate (Southern Biotechnology), goat 
anti-mouse IgG2ab-biotin (Southern Biotechnology) and strepavidin-alkaline 
phosphate (Vector). 
Bone marrow chimeras. All recipients were sub-lethally irradiated with two 
doses of 450 rads and reconstituted via intravenous injections with 2×106 
bone marrow cells. 
In vitro cell stimulation assays. Goat anti-IgM F(ab')2 (Jackson 
Immunoresearch Laboratories), anti-CD40 (Clone 1C10), anti-TCR (Clone 
H57-597), bacterial DNA (CpG) (Geneworks) and lipopolysaccharide, from 
E.coli (Sigma) were used as agonist for stimulation. All cell stimulations were 
done in RPMI supplemented with 10% FCS, 50 units/mL 
penicillin/streptomycin, 10mM HEPES, 10mM sodium pyruvate, 10mM non-
essential MEM and 55 μM β-mercaptoethanol. For DNA synthesis assay, 
2×106 cells were cultured for 48 hours in 96-well flat bottom plates, before 
pulsing with 1 μCi [3H]thymidine for 8 hours. Intracellular calcium was 
measured on an LSR flow cytometer following labelling with Indo-1 (Molecular 
Probes). For labelling with CFSE, cells were diluted to a concentration of 
20×106 cells/mL in PBS and stained with a final concentration of 2.5 μM 
CFSE at 37°C for 10 minutes. Following two washed with cold RPMI, 2×106 
cells were cultured for 48 hours in 96-well flat bottom plates with appropriate 
agonist for 5 days. 
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Western blotting. For B cell purifications, red-cell depleted splenocytes were 
incubated with biotinylated antibodies to CD43 (BD) and B cells were 
negatively selected using strepavidin MACS bead separation (Miltenyi 
Biotech). Cell lysates were subjected to SDS-PAGE with a 12.5% gel using 
the BioRad Mini-Protean II system. Nitrocellulose membranes (Trans-blot 
BioRad) and the BioRad Mini-Protean II system was used for transfer 
according to the manufacturers instructions. Western blotting using the 
following antibodies: donkey anti rabbit IgG F(ab')2-peroxidase (GE 
Healthcare), goat anti mouse IgG F(ab')2-peroxidase (GE Healthcare), mouse 
anti beta-actin monoclonal antibody (Sigma), rabbit anti PKC beta 1 polyclonal 
antibody (Sapphire Biosciences and Cell Signalling), rabbit anti PKC beta 2 
phosphorylated at T642 polyclonal antibody (Sapphire Biosciences) and rabbit 
anti PKC beta 2 polyclonal antibody (Sapphire Biosciences and Cell 
Signalling). Blots were developed using the Western Lightning Western Blot 
Chemiluminescence Reagent (Perkin Elmer).  
Bioinformatics. The following bioinformatic tools were used: Boxshade 3.2.1 
(http://www.ch.embnet.org:80/software/BOX_form.html), ClustalW 
(http://www.ebi.ac.uk/clustalw/), Cn3D (http://0-
www.ncbi.nlm.nih.gov.ilsprod.lib.neu.edu/Structure/CN3D/cn3d.shtml), 
ENSEMBL Genome Browser (http://www.ensembl.org/index.html), Mouse 
Genome Informatics (http://www.informatics.jax.org/) and Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). 
Statistical analysis. Data were analysed using the One-way ANOVA and 
Bonfferonni post-test to compare pairs of columns unless otherwise stated, 
using the GraphPad prism software. Results were considered significant if 
P<0.05. 
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Figure legends 
 
Figure 1. (a) Tilcara strain pedigree and TI-2 antibody response. Open and 
black-filled shapes in pedigree denote third generation (G3) mice with normal 
or low TI-2 responses, respectively, based on ELISA measurement shown on 
right. NP-specific IgM antibodies were measured in 1:150 diluted serum from 
individual G3 mice in the Tilcara pedigree and other ENU6 pedigrees screened 
in parallel, 6 days after immunization with NP-Ficoll. (b) Semi-dominant low 
TI-2 antibody following immunization in G3 offspring from the Tilcara 
pedigree. (c) Informative recombinant Ch7 haplotypes in (CBA×B6til/+)F1×B6+/+ 
mice with low (affected) or normal antibody response to NP-Ficoll. Black, 
homozygous B6 genotype; white, heterozygous CBA/B6 genotype. Maximum 
non-recombinant interval is shown. Map positions refer to Build GRCm38 of 
the mouse genome assembly (http://mouse.ensembl.org). (d) Sequencing 
chromatograms from amplified Prkcb splenic cDNA from mice of the indicated 
genotypes, centred on nucleotide 1654. (e) Semi-dominant low TI-2 antibody 
following immunisation with 2,4,6-trinitrophenyl (TNP)-Ficoll in G3 offspring 
from the Untied pedigree. (f) Location of Tilcara and Untied mutations within 
the human PKCβII kinase domain crystal structure (PDB ID: 210E). (g) 
Location of the S552 residue, Y417 residue and the series of acidic residues 
in helix G that interact with the N-terminal pseudosubstrate domain. The ATP-
binding pocket within the catalytic cleft is also shown. (h) Location of Tilcara 
and Untied mutations with respect to PKCβ protein domains: ps, 
pseudosubstrate inhibitory domain; C1A & C1B, diacylgycerol and 
phospholipid binding domains; C2, calcium binding domain. The green box 
represents the region that differs in PKCβI  PKCβII.  (i) Alignment of amino 
acid sequences of PKCβ from the indicated species (top) and with other 
murine PKC family members (bottom).  
 
Figure 2. (a) Western blot for PKCβI, PKCβII in unstimulated purified B cell 
lysates from wild-type (Prkcbwt/wt), Tilcara heterozygous (Prkcbwt/til) and Tilcara 
homozygous (Prkcbtl/til) mice. (b) Western blot of total NP-40 cell lysates and 
the pellet or supernatant fractions from 293 cells transfected with expression 
Formatted: English (Australia)
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vectors encoding V5-tagged wild-type or S552P mutant PKCβI or PKCβII. 
(c,d) Western blot of lysates from unstimulated B cells of the indicated 
genotypes, probed with (c) antibody to phosphorylated threonine 500 or (d) 
phophorylated threonine 642 in PKCβI. Blots in a, c and d were reprobed with 
β-actin to ensure equal loading. The results are representative of two 
independent experiments analyzing 3-4 mice of each genotype. 
 
Figure 3. Semi-dominant defects in TI-2 antibody but normal TD 
antibody responses in Tilcara.  
(a) NP-binding IgM and IgG3 antibody titres measured 6 days after 
immunization with the TI-2 antigen, NP-Ficoll. (b) Relative concentration of 
basal serum antibodies of the IgM, IgG, IgG1 and IgG3 isotypes. (c) IgG2ab 
and IgG1 isotypes TD antibody titres measured 15 days after primary 
immunization with Bordetella pertussis (BP) and alum precipitated chicken 
gamma globulin coupled to hapten arsonate (ABA-CGG), respectively. For a-
c, relative antibody titres are shown, compared to the mean value in C57BL/6 
control sera set at an arbitrary value of 100. Each dot represents one mouse, 
the bars represent the means for groups of Tilcara mice of the indicated 
genotypes, and error bars represent the standard deviations. *, ** and *** 
indicates a significant difference of P<0.05, P<0.01, P<0.001, respectively, 
calculated by The One-way ANOVA statistical test and Bonferroni post-test. 
The results are representative of three independent experiments. 
 
Figure 4. A representation of flow cytometric plots and percentages 
from Prkcbwt/wt, Prkcbwt/tiland Prkcbtil/til mice for (a) Pro-B/pre-B 
(B220intIgMint), immature (B220intIgMhi) and mature (B220hiIgMhi) B cell 
populations from total lymphocytes for bone marrow cell suspensions. (b) 
Transitional 1 (B220hiCD93hiIgMloCD23lo), transitional 2 
(B220hiCD93hiIgMhiCD23hi), transitional 3 (B220hiCD93hiIgMloCD23hi), follicular 
(B220hiCD93loCD23hiCD21int) and marginal zone 
(B220hiCD93loCD23loCD21int) splenocytes. (c) B-1 cell (IgMhiCD11bhi) 
population in the peritoneal cavity. The histograms show the B-1a (CD5hi) and 
B-1b (CD5lo) cell populations The graphs show the percentages of cells from 
total lymphocytes. *, ** and *** indicates a significant difference of P<0.05, 
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P<0.01, P<0.001, respectively, calculated by The One-way ANOVA statistical 
test and Bonferroni post-test. Results from a-c representative of three 
independent experiments. 
 
Figure 5. Cell autonomous effects of the Tilcara mutation on acute B cell 
response to BCR crosslinking. (a) Intracellular calcium response in 
mixtures of B cells from Prkcbwt/wt CD45.1 and Prkcbtil/til CD45.2 mice in 
response to optimal (50 μg/mL) and sub-optimal (5 and 0.5 μg/mL) 
concentrations of anti-IgM antibody introduced at t=30 s. The vertical axis 
shows the geometric mean fluorescence ratio of calcium-bound Indo-1 (395 
nm, FL5) over un-bound Indo-1 (495 nm, FL4). Paired responses of CD45.1 
and CD45.2 cells are overlaid for each anti-IgM dose. The results are 
representative of three independent experiments. (b and c) Induction of CD25 
on homozygous or heterozygous CD45.2+B220+ cells (open histograms) co-
cultured with CD45.1 wild-type B cells (shaded histograms) for 16 hrs in the 
presence of the indicated stimuli. The mean % positive cells in each culture 
are shown. The results are representative of two independent experiments 
with n = 5 per group. 
 
Figure 6. Effects of Tilcara mutation on induction of B cell proliferation. 
(a-e) Mean (± s.d.) 3H-thymidine incorporation in triplicate cultures of spleen 
cells from five individual mice of the indicated genotypes, 48 hrs after 
stimulation with the indicated agonists. Representative of two independent 
experiments. (f) Cell division measured by dilution of CFSE in wild-type, 
heterozygous and homozygous CD45.2 Prkcbtil/til B cells (open histograms) 
co-cultured with CD45.1 wild-type B cells (shaded histograms) for 5 days with 
the indicated stimuli. Histograms are gated on B220+ CD45.2 or CD45.1 cells. 
(g) The mean percentage of divided CD45.2 cells. The mean±s.d. for the 
percentage of all B cells that were CD45.2+ in unstimulated cultures are: 
70.8±7.7% and 41.8±17.2% for for Prkcbwt/til (n = 5) and Prkcbtil/til (n = 5) 
respectively; for 10μg/mL anti-IgM: 66.6±10.5% and 29.4±15.0%; and for 
1μg/mL anti-IgM+10 μg/mL CD40L 89.6±3.7% and 65.9±8.7%. 
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Supplementary Table 1. At day 0, wild-type (WT) sub-lethally irradiated 
recipients (CD45.1) were reconstituted with bone marrow from wild-type (+/+), 
heterozygous (+/til) or homozygous (til/til) Tilcara donor mice in the following 
combinations - 50% wild-type and 50% wild-type bone marrow, 50% wild-type 
and 50% +/til bone marrow or 50% wild-type and 50% til/til bone marrow. Each 
combination was introduced into five recipient mice (n=5 per group). After 12 
weeks, the mixed hematopoietic chimeras were sacrificed and tested for 
reconstitution of different subpopulations in the bone marrow, spleen and 
peritoneal cavity. For this statistical analysis, the lymphocytes population was 
used as a reference population (the percentages of CD45.1 and CD45.2 
lymphocytes were taken to be the “expected” frequency). The expected 
frequencies were compared to the observe CD45.1 and CD45.2 allotype 
percentages for other subpopulations in the same organ (the “observed” 
frequencies). The P values for a chi-squared test for independence are seen in 
the table. The values were taken to be significant when P<0.05 only in the 
+/+:til/til chimeras, and are denoted by shaded backgrounds. 
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Organ Subpopulation Allotype P-values of chi-squared test from the 
different chimeras 
      +/+:+/+ +/+:+/til +/+:til/til 
Preimmune 
blood CD45R+ B cells CD45.1 0.3534 0.0726 0.8054 
   CD45.2 0.6776 0.2496 0.6906 
  
CD4+ non-B 
cells CD45.1 0.0005 <0.0001 0.0672 
    CD45.2 0.0283 <0.0001 0.0127 
Bone marrow Pro-B/Pre-B CD45.1 0.0007 0.0712 0.0015 
    CD45.2 0.1171 0.5317 0.0361 
  Immature CD45.1 0.2930 0.8242 0.5686 
    CD45.2 0.6678 0.9842 0.5827 
  Mature CD45.1 0.4696 0.1042 0.0002 
    CD45.2 0.8972 0.7091 0.0017 
Spleen CD45R+ B cells CD45.1 0.0512 0.0012 0.8686 
    CD45.2 0.3501 0.0119 0.6143 
  T1 CD45.1 <0.0001 <0.0001 <0.0001 
    CD45.2 <0.0001 <0.0001 <0.0001 
  T2 CD45.1 <0.0001 <0.0001 <0.0001 
    CD45.2 0.0006 <0.0001 <0.0001 
  T3 CD45.1 <0.0001 <0.0001 0.0135 
    CD45.2 0.0011 0.0001 <0.0001 
  B-2 CD45.1 0.1196 0.0009 0.7497 
    CD45.2 0.4797 0.0088 0.5308 
  MZ CD45.1 0.6444 0.6728 <0.0001 
    CD45.2 0.8761 0.7615 <0.0001 
  TCRβ+ cells CD45.1 0.0022 <0.0001 0.7887 
    CD45.2 0.0975 <0.0001 0.4137 
  CD4+ CD45.1 0.0059 <0.0001 0.7968 
    CD45.2 0.1447 <0.0001 0.4393 
  CD8+ CD45.1 <0.0001 <0.0001 0.3180 
    CD45.2 0.0013 <0.0001 0.0411 
Peritoneal cavity CD45R+ B cells CD45.1 0.8300 0.4166 0.9987 
    CD45.2 0.9390 0.5685 0.9900 
  CD5+ IgM- cells CD45.1 <0.0001 <0.0001 0.9267 
    CD45.2 0.0005 <0.0001 0.6339 
  B-1 cells CD45.1 0.4547 0.9226 <0.0001 
    CD45.2 0.7074 0.9586 <0.0001 
  B-1a cells CD45.1 0.1865 0.4777 <0.0001 
    CD45.2 0.4669 0.6400 <0.0001 
  B-1b cells CD45.1 0.6481 0.0533 <0.0001 
    CD45.2 0.8411 0.1359 <0.0001 
 
